Pills that rival biologics, weight-loss drugs paired with psoriasis treatment and a phase 3 win for a personalized mRNA ...

Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the ...

Spread the love“`html Imagine a future where your doctor doesn’t just treat your symptoms, but understands the very blueprint ...

SeaStar Medical Holding Corp. ( ICU ), a commercial-stage healthcare company, said the U.S. FDA has granted Breakthrough Device Designation to its Selective Cytopheretic Device (SCD) therapy for ...

Sen. Rand Paul, R-Ky., released another batch of entries from Dr. Anthony Fauci's personal diary Wednesday dating from ...

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the U.S. Food and Drug Administration ...

As artificial intelligence (AI) becomes increasingly capable of assisting with health care tasks, a new study by researchers ...

Reinsurance Group of America upgraded to Buy after strong underwriting and investment returns. See here for a detailed ...

Countries such as the Solomon Islands and Fiji have pioneered mass drug administration for the disease. Sophie Cousins reports.

NeOnc stands out in this group for the challenge it is confronting. Recurrent high-grade brain cancer remains an exceptionally difficult treatment setting. The National Cancer Institute notes that ...